Search

Craig B. Thompson, Lisa DeAngelis, and Joan Massagué write that as we mark the 50th year of the War on Cancer and look to the future, our mission at Memorial Sloan Kettering is nothing less than conquering the most urgent challenge: preventing cancer’s spread.

… Thursday, July 1, 2021 Dear MSK Community, These are the four most frightening words for a patient to hear: “Your cancer is back.” As we mark the 50th year of the War on Cancer and look to the future, our mission at Memorial Sloan Kettering is nothing less than conquering the most urgent challenge: preventing

The oncology community has stepped up to meet the challenges of the ongoing COVID-19 pandemic but must redouble their efforts in order to stem the potential long-term consequences of this public health crisis on the field.

… Friday, July 17, 2020 The oncology community has stepped up to meet the challenges of the ongoing COVID-19 pandemic but must redouble their efforts in order to stem the potential long-term consequences of this public health crisis on the field. That’s the takeaway from a new letter appearing today in

Discover how an MSK patient coped when she found out her appendiceal cancer had returned.

… Friday, August 31, 2018 Editor’s Note: A busy wife and mother in upstate New York, Christine Buttigieg was diagnosed with appendiceal cancer at a local hospital in 2015. Further testing at MSK revealed that the cancer had spread. After carefully weighing her options, she decided to receive treatment

A major transformation is beginning in cancer surgery that will enable patients to go home within a day of undergoing a significant operation. The new Josie Robertson Surgery Center (JRSC), opened by Memorial Sloan Kettering, exemplifies that transformation: a patient-focused facility that leverages technology and highly trained clinical teams to provide optimal care.

… Monday, December 28, 2015 A major transformation is beginning in cancer surgery that will enable patients to go home within a day of undergoing a significant operation. The new Josie Robertson Surgery Center (JRSC), opened by Memorial Sloan Kettering, exemplifies that transformation: a patient-focused

Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

… Monday, August 13, 2018 Bottom Line: Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors. The new cells combine two of the most promising types of immunotherapy into

The New York Proton Center (NYPC) celebrated its third anniversary, after opening its doors for treatment in August 2019.

… Wednesday, August 17, 2022 Today, the New York Proton Center (NYPC) celebrated its third anniversary, after opening its doors for treatment in August 2019. The New York Proton Center is one of the anchoring projects of the New York City Economic Development Corporation’s plan for creating an innovation

When an immune cell faces a foe, it has more than chemical weapons at its disposal.

… Thursday, May 23, 2019 Summary Scientists at the Sloan Kettering Institute are exploring how physical forces influence cell behavior — in particular, how immune cells use these forces to enhance their killing power. A few years ago, immunologist Morgan Huse made a startling discovery that would set his

Learn about how the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) could provide a new option for patients with metastatic renal cell carcinoma.

… Monday, April 16, 2018 Summary The combination of two immunotherapies outperformed a targeted therapy with regard to overall survival in a phase III study of untreated patients with metastatic renal cell carcinoma (a type of kidney cancer ). Update: On April 16, 2018, the FDA approved the combination

Two studies on multiple myeloma provide new information about diagnosing and treating this blood cancer.

… Monday, December 9, 2019 Summary One study looked at a new drug combination for this blood cancer; the other focused on genetic markers linked to how the disease progresses. Multiple myeloma is a cancer that arises from the type of white blood cells called plasma cells. When normal plasma cells in the

Sloan Kettering Institute investigators have found that a subpopulation of cells within a type of sarcoma called malignant peripheral nerve sheath tumor appear to be similar to a type of neural stem cells.

… Monday, June 14, 2021 Neurofibromatosis type 1 (NF1) is the most common hereditary disease of the nervous system. Overall, it is a rare condition that affects about one in 3,000 people in the United States and worldwide. It is characterized by tumors that grow along the peripheral nerves (the nerves